195 related articles for article (PubMed ID: 21402604)
1. Cost implications of the rapid adoption of newer technologies for treating prostate cancer.
Nguyen PL; Gu X; Lipsitz SR; Choueiri TK; Choi WW; Lei Y; Hoffman KE; Hu JC
J Clin Oncol; 2011 Apr; 29(12):1517-24. PubMed ID: 21402604
[TBL] [Abstract][Full Text] [Related]
2. Cost of New Technologies in Prostate Cancer Treatment: Systematic Review of Costs and Cost Effectiveness of Robotic-assisted Laparoscopic Prostatectomy, Intensity-modulated Radiotherapy, and Proton Beam Therapy.
Schroeck FR; Jacobs BL; Bhayani SB; Nguyen PL; Penson D; Hu J
Eur Urol; 2017 Nov; 72(5):712-735. PubMed ID: 28366513
[TBL] [Abstract][Full Text] [Related]
3. Use of advanced treatment technologies among men at low risk of dying from prostate cancer.
Jacobs BL; Zhang Y; Schroeck FR; Skolarus TA; Wei JT; Montie JE; Gilbert SM; Strope SA; Dunn RL; Miller DC; Hollenbeck BK
JAMA; 2013 Jun; 309(24):2587-95. PubMed ID: 23800935
[TBL] [Abstract][Full Text] [Related]
4. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer.
Sheets NC; Goldin GH; Meyer AM; Wu Y; Chang Y; Stürmer T; Holmes JA; Reeve BB; Godley PA; Carpenter WR; Chen RC
JAMA; 2012 Apr; 307(15):1611-20. PubMed ID: 22511689
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of trends in the cost of initial cancer treatment.
Warren JL; Yabroff KR; Meekins A; Topor M; Lamont EB; Brown ML
J Natl Cancer Inst; 2008 Jun; 100(12):888-97. PubMed ID: 18544740
[TBL] [Abstract][Full Text] [Related]
6. National variation in the delivery of radiation oncology procedures in the non-facility-based setting.
Valle LF; Chu FI; Kundu P; Yoon SM; Gilchrist T; Steinberg ML; Raldow AC
Cancer Med; 2021 Jul; 10(14):4734-4742. PubMed ID: 34076341
[TBL] [Abstract][Full Text] [Related]
7. Racial Differences in Diffusion of Intensity-Modulated Radiation Therapy for Localized Prostate Cancer.
Cobran EK; Chen RC; Overman R; Meyer AM; Kuo TM; O'Brien J; Sturmer T; Sheets NC; Goldin GH; Penn DC; Godley PA; Carpenter WR
Am J Mens Health; 2016 Sep; 10(5):399-407. PubMed ID: 25657192
[TBL] [Abstract][Full Text] [Related]
8. Patterns and correlates of prostate cancer treatment in older men.
Roberts CB; Albertsen PC; Shao YH; Moore DF; Mehta AR; Stein MN; Lu-Yao GL
Am J Med; 2011 Mar; 124(3):235-43. PubMed ID: 21396507
[TBL] [Abstract][Full Text] [Related]
9. Medicare fee reductions and the overuse of intensity-modulated radiotherapy.
Howard DH; Hockenberry J
Health Serv Res; 2021 Aug; 56(4):626-634. PubMed ID: 33905136
[TBL] [Abstract][Full Text] [Related]
10. Communicating Value in Health Care Using Radar Charts: A Case Study of Prostate Cancer.
Thaker NG; Ali TN; Porter ME; Feeley TW; Kaplan RS; Frank SJ
J Oncol Pract; 2016 Sep; 12(9):813-20. PubMed ID: 27577622
[TBL] [Abstract][Full Text] [Related]
11. Association between Site-of-Care and the Cost and Modality of Radiotherapy for Prostate Cancer: Analysis of Medicare Beneficiaries from 2015 to 2017.
Tringale KR; Gennarelli RL; Gillespie EF; Mitchell AP; Zelefsky MJ
Cancer Invest; 2021 Feb; 39(2):144-152. PubMed ID: 33416007
[TBL] [Abstract][Full Text] [Related]
12. Costs of early adjuvant radiation therapy after radical prostatectomy: a decision analysis.
Showalter TN; Foley KA; Jutkowitz E; Lallas CD; Trabulsi EJ; Gomella LG; Dicker AP; Pizzi LT
Ann Oncol; 2012 Mar; 23(3):701-706. PubMed ID: 21659666
[TBL] [Abstract][Full Text] [Related]
13. Association Between Receipt of Definitive Treatment for Localized Prostate Cancer and Adverse Health Outcomes: A Claims-Based Approach.
Mitchell JM; Gresenz CR
Value Health; 2022 Aug; ():. PubMed ID: 35965227
[TBL] [Abstract][Full Text] [Related]
14. Isolating the Drivers of Racial Inequities in Prostate Cancer Treatment.
Hammarlund N; Holt SK; Basu A; Etzioni R; Morehead D; Lee JR; Wolff EM; Gore JL; Nyame YA
Cancer Epidemiol Biomarkers Prev; 2024 Mar; 33(3):435-441. PubMed ID: 38214587
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of concurrent radiation with cetuximab or chemotherapy in older patients with oropharyngeal cancer.
Albarmawi H; Cullen KJ; Mehra R; Onukwugha E; Goloubeva O
J Comp Eff Res; 2022 Jun; 11(8):595-607. PubMed ID: 35543585
[No Abstract] [Full Text] [Related]
16. Comparative effectiveness of new treatment modalities for localized prostate cancer through patient-reported outcome measures.
Zamora V; Garin O; Suárez JF; Gutiérrez C; Guedea F; Cabrera P; Castells M; Herruzo I; Fumadó L; Samper P; Ferrer C; Regis L; Pont À; Ferrer M;
Clin Transl Radiat Oncol; 2024 Jan; 44():100694. PubMed ID: 38021091
[TBL] [Abstract][Full Text] [Related]
17. The cost burden of metastatic prostate cancer in the US populations covered by employer-sponsored health insurance.
Horný M; Yabroff KR; Filson CP; Zheng Z; Ekwueme DU; Richards TB; Howard DH
Cancer; 2023 Oct; 129(20):3252-3262. PubMed ID: 37329254
[TBL] [Abstract][Full Text] [Related]
18. Does Certificate of Need Minimize Intensity Modulated Radiation Therapy Use in Patients with Low Risk Prostate Cancer?
Kim S; Patel AN; Nelson C; Shen S; Mayer T; Moore DF; Lu-Yao GL
Urol Pract; 2016 Sep; 3(5):342-348. PubMed ID: 29057297
[TBL] [Abstract][Full Text] [Related]
19. Promoting the Appropriate Use of Advanced Radiation Technologies in Oncology: Summary of a National Cancer Policy Forum Workshop.
Smith GL; Ganz PA; Bekelman JE; Chmura SJ; Dignam JJ; Efstathiou JA; Jagsi R; Johnstone PA; Steinberg ML; Williams SB; Yu JB; Zietman AL; Weichselbaum RR; Tina Shih YC
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):450-461. PubMed ID: 28011046
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
